

C A N A D A

**PROVINCE OF QUEBEC
DISTRICT OF MONTRÉAL
LOCALITY OF MONTRÉAL**

No: 500-06-001004-197

**SUPERIOR COURT
(Class Action)**

RICCARDO CAMARDA

Plaintiff

v.

ABBOTT LABORATORIES, LIMITED

APOTEX INC.

**ARALEZ PHARMACEUTICALS CANADA
INC.**

BGP PHARMA ULC

BOEHRINGER INGELHEIM (CANADA) LTD.

BRISTOL-MEYERS SQUIBB CANADA CO.

CHURCH & DWIGHT CANADA CORP.

COBALT PHARMACEUTICALS INC.

ETHYPHARM INC.

GLAXOSMITHKLINE INC.

HIKMA LABS INC.

JANSSEN INC.

JODDES LIMITED

LABORATOIRE ATLAS INC.

LABORATOIRE RIVA INC.

LABORATOIRES TRIANON INC.

MERCK FROSST CANADA & CO.

MYLAN PHARMACEUTICALS ULC

NOVARTIS PHARMACEUTICALS CANADA
INC.

PALADIN LABS INC.

PFIZER CANADA ULC

PHARMASCIENCE INC.

PRO DOC LTÉE

PURDUE FREDERICK INC.

PURDUE PHARMA

ROXANE LABORATORIES INC.

SANDOZ CANADA INC.

SANIS HEALTH INC.

SANOFI-AVENTIS CANADA INC.

SUN PHARMA CANADA INC.

TEVA CANADA LIMITED

VALEANT CANADA LIMITED

VALEANT CANADA LP

4490142 CANADA INC., F.K.A. AS MEDA
VALEANT PHARMA CANADA INC.

Defendants

**APPLICATION OF SANDOZ CANADA INC. FOR AUTHORIZATION TO ADDUCE
RELEVANT EVIDENCE
(574 CCP)**

TO THE HONOURABLE JUSTICE GARY D.D. MORRISON OF THE SUPERIOR COURT, ACTING AS THE DESIGNATED JUDGE IN THE PRESENT CASE, THE DEFENDANT SANDOZ CANADA INC. RESPECTFULLY SUBMITS AS FOLLOWS:

1. The Defendant Sandoz Canada Inc. ("**Sandoz**") hereby seeks the authorization of this Honourable Court to adduce relevant evidence pursuant to article 574, paragraph 3 of the *Code of Civil Procedure*, RLRQ c C-25.01 ("**CCP**").

2. More specifically, Sandoz seeks authorization to adduce as relevant evidence a Sworn Statement of Sonia Gallo, Director-Regulatory Affairs, dated March 31, 2021, a copy of which is filed herewith as **Exhibit SZ-1**.
3. As further detailed below, the Sworn Statement (Exhibit SZ-1) is relevant and necessary for the Court's analysis of the criteria of art. 575 CCP, providing essential information regarding the unique regulatory approval process of the generic drugs manufactured by Sandoz and the significant differences between each opioid drug product, as well as serving to correct a false allegation advanced by the Plaintiff.

I. THE AMENDED APPLICATION FOR AUTHORIZATION TO INSTITUTE A CLASS ACTION

4. On or about May 23, 2019, EV (a pseudonym used to protect the anonymity of the plaintiff) filed an *Application for Authorization to Institute a Class Action*.
5. On or about October 25, 2019, an *Amended Application for Authorization to Institute a Class Action* (the "**Amended Authorization Application**") was filed, in which, among other things, the original plaintiff was replaced with Mr. Riccardo Camarda (the "**Plaintiff**"), and additional defendants were added, bringing the total number to 34 named defendants.
6. The Plaintiff seeks the authorization to represent the following proposed class (the "**Class**" or the "**Class Members**"):

"All persons in Quebec who have been prescribed and consumed any one or more of the opioids manufactured, marketed, distributed and/or sold by the Defendants between 1996 and the present day ("**Class Period**") and who suffer or have suffered from Opioid Use Disorder, according to the diagnostic criteria herein described.

The Class includes the direct heirs of any deceased persons who met the above-mentioned description. The Class excludes any person's claim, or any portion thereof, subject to the settlement agreement entered into in the court file no 200-06-000080-070, provided that such settlement agreement becomes effective as a result of the issuance of the requisite court approvals."

7. Without making any distinction whatsoever between the Defendants or the panoply of opioid drug products they are alleged to have manufactured, marketed, distributed and/or sold, the Amended Authorization Application alleges that in an effort to increase the sales of their products, the Defendants deliberately misrepresented that:
 - a) opioids are not as addictive as they truly were;

- b) opioids resulted in improved function and were more effective than other pain relief treatment;
 - c) the withdrawal that could occur when taking opioids could easily be managed;
 - d) opioids were appropriate for long-term use;
 - e) opioids had less adverse effects than other pain management drugs;
 - f) certain opioids provided 12-hour pain relief;
 - g) increased dosages of opioids could be prescribed to combat the effects of end-of-dose failure, without disclosing the risks of the increased dosage; and
 - h) “abuse deterrent” formulations of opioids were effective to prevent abuse.
8. The Amended Authorization Application further alleges, again without making any distinction between the Defendants or the multitude of opioid drug products they are said to have manufactured, sold and/or distributed, that they engaged in aggressive marketing and sales tactics for the distribution of their drugs, and that they were negligent in the research, development, manufacture, testing and regulatory licensing of opioid products in Quebec.
9. The Plaintiff seeks compensatory damages for each Class Member in the amount of \$30,000, punitive damages in the amount of \$25,000,000 from each Defendant as well as pecuniary damages for each Class Member’s personal losses.

II. THE RELEVANCE OF THE SWORN STATEMENT OF SONIA GALLO

10. Sandoz seeks this Honourable Court’s permission to file the Sworn Statement of Sonia Gallo, Director-Regulatory Affairs (Exhibit SZ-1), in order to provide this Court with the relevant and necessary factual context regarding the some material differences in the regulatory approval process for an innovator drug and the generic versions of those innovator drugs, and between each of Sandoz’s multiple named opioid drug products, as well as to correct one of the false allegations advanced in the Amended Authorization Application.
11. Indeed, the Amended Authorization Application completely ignores the rigorous regulatory approval process by Health Canada that precedes the sale of drugs in Canada.
12. The Amended Authorization Application also ignores the differences between the 34 Defendants named in the Amended Authorization Application, which includes innovator and generic drug manufacturers, sellers and/or distributors, as well as the many differences between the exceedingly large number of drug

products and/or categories of drugs they are said to have manufactured marketed and/or sold, and falsely assumes and alleges that they have all committed the same alleged faults or misrepresentations.

13. The Sworn Statement (Exhibit SZ-1) serves to:
 - a) explain some material differences between “brand name” drugs - also referred to as “innovator” or “original” drugs, and “generic” drugs;
 - b) demonstrate that each specific drug requires a different regulatory approval process and that Sandoz had to go through this regulatory process for each of its opioid drug products;
 - c) demonstrate that the opioid drug products differ from one another in many different respects, including notably their use, dosage, forms and strengths, the ways they administered/ingested and regarding their specific contraindications, precautions and warnings;
 - d) correct a false statement regarding the manufacture of Fiorinal by Sandoz during the Class Period.
14. With respect to the regulatory process of drug approval, the Sworn Statement (Exhibit SZ-1) clarifies that:
 - a) The process for an innovator drug to obtain approval from Health Canada to sell its drugs in Canada differs from the regulatory approval process applicable to suppliers of generic versions of those innovator drugs;
 - b) The innovator drug regulatory approval process includes assessing information and data about the drug’s safety, effectiveness, and quality;
 - c) The product monograph of a drug is also approved by Health Canada;
 - d) The regulatory review process for a generic drug does **not** require the generic drug supplier to provide safety and efficacy studies. Instead, the generic drug supplier only needs to establish that its proposed generic drug is a bioequivalent of the innovator drug;
 - e) Sandoz underwent the regulatory process for each of the generic opioid drugs it manufactures and/or sells and obtained from Health Canada regulatory approval to manufacture and sell those drugs; and;
 - f) Generic opioid drug products differ in various respects: they are indicated for different purposes, produced in different dosages,

administered/ingested differently, and they each have a different product monograph.

15. The important distinctions between the regulatory approval process of Health Canada with respect to generic drugs and innovator drugs and between the different opioid drug products are relevant and essential to this Court's determination of whether the Amended Authorization Application has demonstrated that the claims of the Class Members in fact raise identical, similar or related issues of law or fact pursuant to article 575(1) CCP, and whether the Plaintiff has in fact demonstrated an arguable case against each of the 34 Defendants as required by article 575(2) CCP.
16. As drafted, the Amended Authorization Application is based on the patently false assumption, among other things, that:
 - a) any and all opioid drug products and product monographs are interchangeable (as demonstrated by the conscious choice of the Plaintiff not to include in its Amended Authorization Application all the product monographs of the different drugs for the different Defendants);
 - b) the risks of the different opioid drug products are the same for any opioid drug product;
 - c) the marketing of any opioid drug product and/or by each of the Defendants is done in the same way;
 - d) the obligations of all of the 34 named Defendants are exactly the same, regardless of the nature of a given Defendant's business and the nature of the opioid drug product at issue;
 - e) the Defendants have all committed the same alleged faults.
17. The Plaintiff plainly ignores and/or diminishes the very real and important differences between the Defendants and each of the many different opioid drug products they are alleged to have manufactured, sold and/or distributed.
18. As such, the Sworn Statement (Exhibit SZ-1) provides the relevant and necessary information and the complete factual matrix regarding the important differences between the Defendants, their obligations, and the various opioid drug products that Sandoz manufactures, sells and/or distributes, thus assisting this Honourable Court in its analysis of the criteria of article 575 CCP.
19. In addition to providing these essential explanations, Sonia Gallo's Sworn Statement also serves to correct a false allegation of the Amended Authorization Application.

20. Specifically, the Sworn Statement (Exhibit SZ-1) confirms that contrary to the allegations of the Amended Authorization Application, Sandoz did not manufacture, market and/or sell Fiorinal C1/2 or Fiorinal C1/4 during the Class Period.
21. The Sworn Statement (Exhibit SZ-1) will thus assist this Honourable Court in its analysis of the authorization criteria, and specifically in its determination of whether the claims of the Class Members raise identical, similar or related issues of law or fact pursuant to article 575 (1) CCP, and whether Plaintiff has established an appearance of right pursuant to article 575 (2) CCP.
22. The relevant evidence, which Sandoz seeks this Court's authorization to submit, also satisfies the principle of proportionality required by article 18 and 19 CCP.
23. The present Application is well founded in fact and in law.

FOR THESE REASONS, MAY IT PLEASE THIS COURT TO:

GRANT the present Application;

AUTHORIZE the Defendant Sandoz Canada Inc. to file the Sworn Statement of Sonia Gallo, Director-Regulatory Affairs, dated March 31, 2021, a copy of which is filed herewith as **Exhibit SZ-1**;

THE WHOLE without legal costs, unless the present Application is contested.

Montréal, this March 31, 2021



Fasken Martineau DuMoulin LLP

Attorneys for Sandoz Canada Inc.

800 Victoria Square, Suite 3500

P.O. Box 242

Montréal, Quebec H4Z 1E9

Fax number: +1 514 397 7600

Mtre Noah Boudreau

Phone number: +1 514 394 4521

Email: nboudreau@fasken.com

Mtre Mirna Kaddis

Phone number: +1 514 397 7484

Email: mkaddis@fasken.com

C A N A D A

**PROVINCE OF QUEBEC
DISTRICT OF MONTRÉAL
LOCALITY OF MONTRÉAL**

No: 500-06-001004-197

**SUPERIOR COURT
(Class Action)**

RICCARDO CAMARDA

Plaintiff

v.

ABBOTT LABORATORIES, LIMITED

APOTEX INC.

**ARALEZ PHARMACEUTICALS CANADA
INC.**

BGP PHARMA ULC

BOEHRINGER INGELHEIM (CANADA) LTD.

BRISTOL-MEYERS SQUIBB CANADA CO.

CHURCH & DWIGHT CANADA CORP.

COBALT PHARMACEUTICALS INC.

ETHYPHARM INC.

GLAXOSMITHKLINE INC.

HIKMA LABS INC.

JANSSEN INC.

JODDES LIMITED

LABORATOIRE ATLAS INC.

LABORATOIRE RIVA INC.

LABORATOIRES TRIANON INC.

MERCK FROSST CANADA & CO.

MYLAN PHARMACEUTICALS ULC

**NOVARTIS PHARMACEUTICALS CANADA
INC.**

PALADIN LABS INC.

PFIZER CANADA ULC

PHARMASCIENCE INC.

PRO DOC LTÉE

PURDUE FREDERICK INC.

PURDUE PHARMA

ROXANE LABORATORIES INC.

SANDOZ CANADA INC.

SANIS HEALTH INC.

SANOFI-AVENTIS CANADA INC.

SUN PHARMA CANADA INC.

TEVA CANADA LIMITED

VALEANT CANADA LIMITED

VALEANT CANADA LP

**4490142 CANADA INC., F.K.A. AS MEDA
VALEANT PHARMA CANADA INC.**

Defendants

LIST OF EXHIBITS

EXHIBIT SZ-1. : Copy of the Sworn Statement of Sonia Gallo, Director-Regulatory Affairs, dated March 31, 2021

Montréal, this March 31, 2021

Fasken Martineau DuMoulin

Fasken Martineau DuMoulin LLP

Attorneys for Sandoz Canada Inc.

800 Victoria Square, Suite 3500

P.O. Box 242

Montréal, Quebec H4Z 1E9

Fax number: +1 514 397 7600

Mtre Noah Boudreau

Phone number: +1 514 394 4521

Email: nboudreau@fasken.com

Mtre Mirna Kaddis

Phone number: +1 514 397 7484

Email: mkaddis@fasken.com

EXHIBIT SZ-1

C A N A D A

**PROVINCE OF QUEBEC
DISTRICT OF MONTRÉAL
LOCALITY OF MONTRÉAL**

No: 500-06-001004-197

**SUPERIOR COURT
(Class Action)**

RICCARDO CAMARDA

Plaintiff

V.

ABBOTT LABORATORIES, LIMITED

APOTEX INC.

**ARALEZ PHARMACEUTICALS CANADA
INC.**

BGP PHARMA ULC

BOEHRINGER INGELHEIM (CANADA) LTD.

BRISTOL-MEYERS SQUIBB CANADA CO.

CHURCH & DWIGHT CANADA CORP.

COBALT PHARMACEUTICALS INC.

ETHYPHARM INC.

GLAXOSMITHKLINE INC.

HIKMA LABS INC.

JANSSEN INC.

JODDES LIMITED

LABORATOIRE ATLAS INC.

LABORATOIRE RIVA INC.

LABORATOIRES TRIANON INC.

MERCK FROSST CANADA & CO.

MYLAN PHARMACEUTICALS ULC

NOVARTIS PHARMACEUTICALS CANADA
INC.

PALADIN LABS INC.

PFIZER CANADA ULC

PHARMASCIENCE INC.

PRO DOC LTÉE

PURDUE FREDERICK INC.

PURDUE PHARMA

ROXANE LABORATORIES INC.

SANDOZ CANADA INC.

SANIS HEALTH INC.

SANOFI-AVENTIS CANADA INC.

SUN PHARMA CANADA INC.

TEVA CANADA LIMITED

VALEANT CANADA LIMITED

VALEANT CANADA LP

4490142 CANADA INC., F.K.A. AS MEDA
VALEANT PHARMA CANADA INC.

Defendants

SWORN STATEMENT

I, Sonia Gallo, Director-Regulatory Affairs, having my professional address at 110 de Lauzon Street, in the city of Boucherville, in the Province of Quebec, do solemnly declare:

1. I make this Sworn Statement in support of the Defendant Sandoz Canada Inc.'s ("**Sandoz**") *Application for Authorization to Adduce Relevant Evidence*.
2. I have reviewed the *Amended Application for Authorization to Institute a Class Action, and to Obtain the Status of Representative* (the "**Amended Authorization Application**").

3. Sandoz conducts business of manufacturing and selling generic versions of “brand name” drugs. “Generic” drugs are distinct from “brand name” drugs—also referred to as “innovator” or “original” drugs. Innovator drugs have patent protection and a specified period of exclusivity in the market. Generally, the generic drug manufacturers commence selling generic versions of the innovator’s drug after expiry of the patent.
4. The manufacture and supply of drugs in Canada is regulated by, among other entities, the federal department of health, known as “Health Canada”. The process for a supplier of an innovator drug to obtain approval from Health Canada to sell its drugs in Canada differs in some respects from the regulatory approval process applicable to suppliers of generic versions of those innovator drugs.
5. Before an innovator’s prescription drug can be brought to market in Canada, it undergoes a stringent regulatory approval process administered by “Health Canada”, which includes assessing information and data about the drug’s safety, effectiveness, and quality.
6. If, at the conclusion of this regulatory approval process, Health Canada is satisfied that the benefits of a drug outweigh its risks, Health Canada will issue a marketing authorization, in the form of a Notice of Compliance or Drug Identification Number, which formally certifies that the drug has successfully completed the regulatory review process and that the drug and its associated product monograph (or prescribing information) comply with the *Food and Drugs Act*, R.S.C., 1985, c. F-27, and the Regulations enacted pursuant to the *Food and Drugs Act*.
7. A drug’s product monograph/prescribing information, which is approved as part of the regulatory approval process, contains information about the drug for healthcare professionals and consumers, including benefits and any known risks, contraindications, warnings, drug interactions, and precautions associated with the consumption of the drug.
8. Health Canada regulates and controls the information contained in a product monograph/prescribing information, and this information must be approved by Health Canada before a drug may be sold in Canada. Among other things, all benefits and risks listed in a product monograph/prescribing information must be approved by Health Canada. Similarly, all revisions and updates to a product monograph/prescribing information also are subject to a stringent review and approval process by Health Canada.
9. Generic drug suppliers follow a similar regulatory approval process before they may bring a generic drug to market in Canada. However, the regulatory review process for a proposed generic drug does not require the generic drug supplier to provide safety and efficacy studies. Instead, the generic drug supplier only needs to establish that its proposed generic drug is a bioequivalent of the innovator drug

(i.e. it contains the same active ingredients and is as safe and effective as the innovator drug).

10. For each of the generic opioid drug products that are listed in paragraphs 2.30 and 2.30.1 of the Amended Authorization Application (with the exception of Fiorinal C1/2 or Fiorinal C1/4, which, contrary to what is alleged in paragraph 2.30 of the Amended Authorization Application, Sandoz never manufactured, marketed and/or sold during the Class Period (as that term is defined in the Amended Authorization Application)), Sandoz underwent the process, described above, of obtaining from Health Canada regulatory approval to manufacture and sell those drugs.
11. The generic opioid drug products listed in paragraphs 2.30 and 2.30.1 of the Amended Authorization Application differ from one another in various respects. They were indicated for different purposes ranging from management of different types of pain to inducing and maintaining anesthesia for patients undergoing surgery; they were produced during different periods of time; they were produced in different dosage forms and strengths; they were administered/ingested differently; and they had different product monographs with different specific contraindications, precautions and warnings.
12. All the facts alleged in this Sworn Statement are true to my knowledge.

AND I HAVE SIGNED :

Digitally signed by Gallo Sonia
DN: dc=com, dc=novartis,
ou=people, ou=GX,
serialNumber=821052, cn=Gallo
Sonia
Date: 2021.03.31 16:08:02 -04'00'

Gallo Sonia

SONIA GALLO

Solemnly affirmed before me,
in Montréal, on March 31, 2021


Commissioner for Oaths for Québec



Candide Sara Pelletier

De: Candide Sara Pelletier
Envoyé: 31 mars 2021 16:21
À: afishman@ffmp.ca; mmeland@ffmp.ca; msiminovitch@ffmp.ca; tsilverstein@ffmp.ca; notification@ffmp.ca; andre@tjl.quebec; gabrielle@tjl.quebec; mgagne@mccarthy.ca; epoupart@mccarthy.ca; notification@mccarthy.ca; aboctor@imk.ca; jmboudreau@imk.ca; hradomski@goodmans.ca; ndeluca@goodmans.ca; mouanounou@goodmans.ca; maudren@audrenrolland.com; mgrou@audrenrolland.com; notification@audrenrolland.com; joseane.chretien@mcmillan.ca; gabrielle.lachance-touchette@mcmillan.ca; pablo.guzman@dlapiper.com; tania.dasilva@dlapiper.com; lcharette@lavery.ca; mbixi@lavery.ca; notifications-mtl@lavery.ca; aauthier@osler.com; eprefontaine@osler.com; jharding@osler.com; notificationosler@osler.com; pouellet@woods.qc.ca; cmaughan@woods.qc.ca; notification@woods.qc.ca; guy.poitras@gowlingwlg.com; joelle.boisvert@gowlingwlg.com; vincent.deletoile@langlois.ca; elisabeth.neelin@langlois.ca; notificationmtl@langlois.ca; robert.torralbo@blakes.com; ariane.bisaillon@blakes.com; pfernet@fernet.ca; cdubord@fernet.ca; Claude.marseille@blakes.com; Matthew.millmanpilon@blakes.com; Noah Boudreau; Peter J. Pliszka; kbrabander@mccarthy.ca; notification@mccarthy.ca; wmcnamara@torys.com; notifications-mtl@torys.com; yrobillard@millerthomson.com; famine@millerthomson.com; jsaintonge@blg.com; amerminod@blg.com; pplante@blg.com; notification@blg.com; dmitchell@imk.ca; slavoie@imk.ca; Fallon, Alexandre; Morissette, Julien; Glendinning, Deborah; O'Brien, Kevin; Hirsh, Adam; notificationosler@osler.com; srodrigue@torys.com; Manolecmanole@torys.com; mgingras@torys.com; notifications-mtl@torys.com; francis.rouleau@blakes.com; anthony.cayer@blakes.com; andrew.skodyn@blakes.com; melanie.baird@blakes.com
Cc: Noah Boudreau; Mirna Kaddis; Peter J. Pliszka
Objet: Notification - Riccardo Camarda v. Abbott Laboratories, Limited and al. - 500-06-001004-197 - Our ref. : 278131.00014
Pièces jointes: 2021-03-31 - Application for Authorization to Adduce Relevant Evidence.pdf

Suivi:	Destinataire	Réception
	afishman@ffmp.ca	
	mmeland@ffmp.ca	
	msiminovitch@ffmp.ca	
	tsilverstein@ffmp.ca	
	notification@ffmp.ca	
	andre@tjl.quebec	
	gabrielle@tjl.quebec	
	mgagne@mccarthy.ca	
	epoupart@mccarthy.ca	
	notification@mccarthy.ca	
	aboctor@imk.ca	
	jmboudreau@imk.ca	

Destinataire

Réception

hradomski@goodmans.ca
 ndeluca@goodmans.ca
 mouanounou@goodmans.ca
 maudren@audrenrolland.com
 mgrou@audrenrolland.com
 notification@audrenrolland.com
 joseane.chretien@mcmillan.ca
 gabrielle.lachance-touchette@mcmillan.ca
 pablo.guzman@dlapiper.com
 tania.dasilva@dlapiper.com
 lcharette@lavery.ca
 mbixi@lavery.ca
 notifications-mtl@lavery.ca
 aauthier@osler.com
 eprefontaine@osler.com
 jharding@osler.com
 notificationosler@osler.com
 pouellet@woods.qc.ca
 cmaughan@woods.qc.ca
 notification@woods.qc.ca
 guy.poitras@gowlingwlg.com
 joelle.boisvert@gowlingwlg.com
 vincent.deletoile@langlois.ca
 elisabeth.neelin@langlois.ca
 notificationmtl@langlois.ca
 robert.torralbo@blakes.com
 ariane.bisaillon@blakes.com
 pfernet@fernet.ca
 cdubord@fernet.ca
 Claude.marseille@blakes.com
 Matthew.millmanpilon@blakes.com
 Noah Boudreau
 Peter J. Pliszka
 kbrabander@mccarthy.ca
 notification@mccarthy.ca
 wmcnamara@torys.com
 notifications-mtl@torys.com
 yrobillard@millerthomson.com
 famine@millerthomson.com

Remis: 2021-03-31 16:21

Remis: 2021-03-31 16:21

Destinataire

Réception

jsaintonge@blg.com
amerminod@blg.com
pplante@blg.com
notification@blg.com
dmitchell@imk.ca
slavoie@imk.ca
Fallon, Alexandre
Morissette, Julien
Glendinning, Deborah
O'Brien, Kevin
Hirsh, Adam
notificationosler@osler.com
srodrigue@torys.com
Manolecmanole@torys.com
mgingras@torys.com
notifications-mtl@torys.com
francis.rouleau@blakes.com
anthony.cayer@blakes.com
andrew.skodyn@blakes.com
melanie.baird@blakes.com
Noah Boudreau
Mirna Kaddis
Peter J. Pliszka

Remis: 2021-03-31 16:21

NOTIFICATION BY TECHNOLOGICAL MEANS

Fasken Martineau DuMoulin LLP
(Art. 133 - 134 of the *Code of Civil Procedure*, CQLR c. C-25.01)

Parties : Riccardo Camarda v. Abbott Laboratories, Limited and al.
Court: Superior Court
Judicial District: Montréal
Locality: Montréal
Court Number: 500-06-001004-197

Sender:	Noah Boudreau +1 514 394 4521 nboudreau@fasken.com Our ref.: 278131.00014	Fasken Martineau DuMoulin 800 Victoria Square, Suite 3500 P.O. Box 242 Montréal, Quebec H4Z 1E9
----------------	--	---

Recipient(s):

Me Avram Fishman	FISHMAN FLANZ	afishman@ffmp.ca
Me Mark E. Meland	MELAND PAQUIN	
	FISHMAN FLANZ	mmeland@ffmp.ca
	MELAND PAQUIN	
Me Margo R. Siminovitch	FISHMAN FLANZ	msiminovitch@ffmp.ca
	MELAND PAQUIN	
Me Tina Silverstein	FISHMAN FLANZ	tsilverstein@ffmp.ca
	MELAND PAQUIN	
Me André Lespérance	TRUDEL JOHNSTON & LESPÉRANCE	andre@tjl.quebec
Me Gabrielle Gagné	TRUDEL JOHNSTON & LESPÉRANCE	gabrielle@tjl.quebec
Me Michel Gagné	McCARTHY TÉTRAULT	mgagne@mccarthy.ca
Me Emmanuelle Poupart	McCARTHY TÉTRAULT	epoupart@mccarthy.ca
Me Audrey Boctor	IMK	aboctor@imk.ca
Me Jean-Michel Boudreau	IMK	jmboudreau@imk.ca
Me Harry Radomski	GOODMANS	hradomski@goodmans.ca
Me Nando De Luca	GOODMANS	ndeluca@goodmans.ca
Me Melanie Ouanounou	GOODMANS	mouanounou@goodmans.ca
Me Marie Audren	AUDREN ROLLAND	maudren@audrenrolland.com
Me Marc-andré Grou	AUDREN ROLLAND	mgrou@audrenrolland.com
Me Joséane Chretien	McMILLAN	joseane.chretien@mcmillan.ca
Me Gabrielle Lachance	McMILLAN	gabrielle.lachance-
Touchette		touchette@mcmillan.ca
Me Tania da Silva	DLA PIPER (CANADA)	tania.dasilva@dlapiper.com
Me Pablo Guzman	DLA PIPER (CANADA)	pablo.guzman@dlapiper.com
Me Myriam Brixi	LAVERY DE BILLY	mbrixi@lavery.ca
Me Louis Charette	LAVERY DE BILLY	lcharette@lavery.ca
Me Éric Préfontaine	OSLER, HOSKIN & RANCOURT	eprefontaine@osler.com;
Me Jessica Harding	OSLER, HOSKIN & RANCOURT	jharding@osler.com
Annie-Claude Authier	OSLER, HOSKIN & RANCOURT	aauthier@osler.com
Me Christopher Maughan	WOODS	cmaughan@woods.qc.ca;
Me Patrick Ouellet	WOODS	pouellet@woods.qc.ca;
Me Guy Poitras	GOWLING WLG	guy.poitras@gowlingwlg.com
Me Joëlle Boisvert	GOWLING WLG	joelle.boisvert@gowlingwlg.com
Me Vincent de l'Étoile	LANGLOIS AVOCATS	vincent.deletoile@langlois.ca;
Me Élisabeth Neelin	LANGLOIS AVOCATS	elisabeth.neelin@langlois.ca;

Me Robert J. Torralbo	BLAKE, CASSEL & GRAYDON	robert.torralbo@blakes.com;
Me Ariane Bisailon	BLAKE, CASSEL & GRAYDON	ariane.bisailon@blakes.com
Me Paul Fernet	FERNET AVOCATS INC.	pfernet@fernet.ca;
Me Catherine Dubord	FERNET AVOCATS INC.	cdubord@fernet.ca
Me Matthew Millman-Pilon	BLAKE, CASSEL & GRAYDON	Matthew.millmanpilon@blakes.com
Me Claude Marseille	BLAKE, CASSEL & GRAYDON	Claude.marseille@blakes.com
Me Kristian Brabander	McCARTHY TÉTRAULT	kbrabander@mccarthy.ca
Me William McNamara	SOCIÉTÉ D'AVOCATS TORYS	wmcnamara@torys.com;
Me Fadi Amine	MILLER THOMSON	famine@millerthomson.com;
Yves Robillard	MILLER THOMSON	yrobillard@millerthomson.com;
Me Jean Saint-Onge	BORDEN LADNER GERVAIS	jsaintonge@blg.com;
Me Patrick Plante	BORDEN LADNER GERVAIS	pplante@blg.com
Me Anne Merminod	BORDEN LADNER GERVAIS	amerminod@blg.com;
Me Doug Mitchell	IMK	dmitchell@imk.ca
Me Samuel Lavoie	IMK	slavoie@imk.ca
Me Alexandre Fallon	OSLER, HOSKIN & RANCOURT	AFallon@osler.com
Me Julien Morissette	OSLER, HOSKIN & RANCOURT	JMorissette@osler.com
Me Deborah Glendinning	OSLER, HOSKIN & RANCOURT	DGlendinning@osler.com
Me Kevin O'Brien	OSLER, HOSKIN & RANCOURT	KOBrien@osler.com
Me Adam Hirsh	OSLER, HOSKIN & RANCOURT	AHirsh@osler.com
Me Sylvie Rodrigue	SOCIÉTÉ D'AVOCATS TORYS	srodrigue@torys.com;
Me Corina Manole	SOCIÉTÉ D'AVOCATS TORYS	Manolecmanole@torys.com;
Me Marie-Eve Gingras	SOCIÉTÉ D'AVOCATS TORYS	mgingras@torys.com;
Me Francis Rouleau	BLAKE, CASSELS & GRAYDON	francis.rouleau@blakes.com
Me Anthony Cayer	BLAKE, CASSELS & GRAYDON	anthony.cayer@blakes.com

Me Andrew Skodyn	BLAKE, CASSELS & GRAYDON	andrew.skodyn@blakes.com
Me Mélanie Baird	BLAKE, CASSELS & GRAYDON	melanie.baird@blakes.com

Information of the notified document(s):

Document's Title	Type	Nb pages	Size
2021-03-31 - Application for authorization to adduce relevant evidence (art. 574 CCP)	PDF	16	229 KB

Please contact the sender if you have any technical problems with the documents.

 Candide Sara Pelletier
LEGAL ASSISTANT

FASKEN

Fasken Martineau DuMoulin S.E.N.C.R.L., s.r.l.
T. +1 514 397 7492 | F. 1 514 397 7600
cpelletier@fasken.com | www.fasken.com
800, rue du Square-Victoria, bureau 3500, Montréal, Québec H4Z 1E9

De: Microsoft Outlook
À: afishman@ffmp.ca; msiminovitch@ffmp.ca; tsilverstein@ffmp.ca;
notification@ffmp.ca; andre@tjl.quebec; gabrielle@tjl.quebec; mgagne@mccarthy.ca;
epoupart@mccarthy.ca; notification@mccarthy.ca; aboctor@imk.ca;
jmboudreau@imk.ca; hradomski@goodmans.ca; ndeluca@goodmans.ca;
mouanounou@goodmans.ca; andrew.skodyn@blakes.com;
maudren@audrenrolland.com; notification@audrenrolland.com;
joseane.chretien@mcmillan.ca; gabrielle.lachance-touchette@mcmillan.ca;
pablo.guzman@dlapiper.com; tania.dasilva@dlapiper.com; lcharette@lavery.ca;
mbrixi@lavery.ca; notifications-mtl@lavery.ca; aauthier@osler.com;
eprefontaine@osler.com; jharding@osler.com; notificationosler@osler.com;
pouellet@woods.qc.ca; cmaughan@woods.qc.ca; mmeland@ffmp.ca;
notification@woods.qc.ca; guy.poitras@gowlingwlg.com;
joelle.boisvert@gowlingwlg.com; elisabeth.neelin@langlois.ca;
notificationmtl@langlois.ca; robert.torralbo@blakes.com;
ariane.bisaillon@blakes.com; pfernet@fernet.ca; cdubord@fernet.ca;
Claude.marseille@blakes.com; Matthew.millmanpilon@blakes.com;
kbrabander@mccarthy.ca; wmcnamara@torys.com; notifications-mtl@torys.com;
yrobillard@millerthomson.com; famine@millerthomson.com; jsaintonge@blg.com;
mgrou@audrenrolland.com; amerminod@blg.com; notification@blg.com;
dmitchell@imk.ca; slavoie@imk.ca; Fallon, Alexandre; Morissette, Julien; Glendinning,
Deborah; O'Brien, Kevin; Hirsh, Adam; srodrigue@torys.com;
Manolecmanole@torys.com; mgingras@torys.com; francis.rouleau@blakes.com;
anthony.cayer@blakes.com; vincent.deletoile@langlois.ca; pplante@blg.com;
melanie.baird@blakes.com
Envoyé: 31 mars 2021 16:21
Objet: Relayé : Notification - Riccardo Camarda v. Abbott Laboratories, Limited and al. -
500-06-001004-197 - Our ref. : 278131.00014

La remise à ces destinataires ou groupes est terminée, mais aucune notification de remise n'a été envoyée par le serveur de destination :

afishman@ffmp.ca (afishman@ffmp.ca)

msiminovitch@ffmp.ca (msiminovitch@ffmp.ca)

tsilverstein@ffmp.ca (tsilverstein@ffmp.ca)

notification@ffmp.ca (notification@ffmp.ca)

andre@tjl.quebec (andre@tjl.quebec)

gabrielle@tjl.quebec (gabrielle@tjl.quebec)

mgagne@mccarthy.ca (mgagne@mccarthy.ca)

epoupart@mccarthy.ca (epoupart@mccarthy.ca)

notification@mccarthy.ca (notification@mccarthy.ca)

aboctor@imk.ca (aboctor@imk.ca)

jmboudreau@imk.ca (jmboudreau@imk.ca)

hradomski@goodmans.ca (hradomski@goodmans.ca)

ndeluca@goodmans.ca (ndeluca@goodmans.ca)

mouanounou@goodmans.ca (mouanounou@goodmans.ca)

andrew.skodyn@blakes.com (andrew.skodyn@blakes.com)

maudren@audrenrolland.com (maudren@audrenrolland.com)

notification@audrenrolland.com (notification@audrenrolland.com)

joseane.chretien@mcmillan.ca (joseane.chretien@mcmillan.ca)

gabrielle.lachance-touchette@mcmillan.ca (gabrielle.lachance-touchette@mcmillan.ca)

pablo.guzman@dlapiper.com (pablo.guzman@dlapiper.com)

tania.dasilva@dlapiper.com (tania.dasilva@dlapiper.com)

lcharette@lavery.ca (lcharette@lavery.ca)

mbixi@lavery.ca (mbixi@lavery.ca)

notifications-mtl@lavery.ca (notifications-mtl@lavery.ca)

aauthier@osler.com (aauthier@osler.com)

eprefontaine@osler.com (eprefontaine@osler.com)

jharding@osler.com (jharding@osler.com)

notificationosler@osler.com (notificationosler@osler.com)

pouellet@woods.qc.ca (pouellet@woods.qc.ca)

cmaughan@woods.qc.ca (cmaughan@woods.qc.ca)

mmeland@ffmp.ca (mmeland@ffmp.ca)

notification@woods.qc.ca (notification@woods.qc.ca)

guy.poitras@gowlingwlg.com (guy.poitras@gowlingwlg.com)

joelle.boisvert@gowlingwlg.com (joelle.boisvert@gowlingwlg.com)

elisabeth.neelin@langlois.ca (elisabeth.neelin@langlois.ca)

notificationmtl@langlois.ca (notificationmtl@langlois.ca)

robert.torralbo@blakes.com (robert.torralbo@blakes.com)

ariane.bisaillon@blakes.com (ariane.bisaillon@blakes.com)

pfernet@fernet.ca (pfernet@fernet.ca)

cdubord@fernet.ca (cdubord@fernet.ca)

Claude.marseille@blakes.com (Claude.marseille@blakes.com)

Matthew.millmanpilon@blakes.com (Matthew.millmanpilon@blakes.com)

kbrabander@mccarthy.ca (kbrabander@mccarthy.ca)

wmcnamara@torys.com (wmcnamara@torys.com)

notifications-mtl@torys.com (notifications-mtl@torys.com)

yrobillard@millerthomson.com (yrobillard@millerthomson.com)

famine@millerthomson.com (famine@millerthomson.com)

jsaintonge@blg.com (jsaintonge@blg.com)

mgrou@audrenrolland.com (mgrou@audrenrolland.com)

amerminod@blg.com (amerminod@blg.com)

notification@blg.com (notification@blg.com)

dmitchell@imk.ca (dmitchell@imk.ca)

slavoie@imk.ca (slavoie@imk.ca)

[\(AFallon@osler.com\)](mailto:Fallon, Alexandre (AFallon@osler.com))

[\(JMorissette@osler.com\)](mailto:Morissette, Julien (JMorissette@osler.com))

[\(DGlendinning@osler.com\)](mailto:Glendinning, Deborah (DGlendinning@osler.com))

[\(KOBrien@osler.com\)](mailto:O'Brien, Kevin (KOBrien@osler.com))

[\(AHirsh@osler.com\)](mailto:Hirsh, Adam (AHirsh@osler.com))

srodrigue@torys.com (srodrigue@torys.com)

Manolecmanole@torys.com (Manolecmanole@torys.com)

mgingras@torys.com (mgingras@torys.com)

francis.rouleau@blakes.com (francis.rouleau@blakes.com)

anthony.cayer@blakes.com (anthony.cayer@blakes.com)

vincent.deletoile@langlois.ca (vincent.deletoile@langlois.ca)

pplante@blg.com (pplante@blg.com)

melanie.baird@blakes.com (melanie.baird@blakes.com)

Objet : Notification - Riccardo Camarda v. Abbott Laboratories, Limited and al. - 500-06-001004-197 - Our ref. : 278131.00014



Notification -
Riccardo Camar...

N° : 500-06-001004-197

PROVINCE OF QUEBEC
SUPERIOR COURT
(Class Action)
DISTRICT OF MONTRÉAL
LOCALITY OF MONTRÉAL

RICCARDO CAMARDA

Plaintiff

v.

**ABBOTT LABORATORIES, LIMITED AND
AL.**

Defendants

16989/278131.00014

BF1339

**APPLICATION FOR AUTHORIZATION TO
ADDUCE RELEVANT EVIDENCE
(ART. 574 CCP),
LIST OF EXHIBITS AND EXHIBIT SZ-1**

(Class Action)

ORIGINAL

Fasken Martineau DuMoulin LLP

800 Victoria Square, Suite 3500
P.O. Box 242
Montréal, Quebec H4Z 1E9

Me Noah Boudreau
nboudreau@fasken.com

Tél. +1 514 394 4521
Fax. +1 514 397 7600

Me Mirna Kaddis
mkaddis@fasken.com

Tél. +1 514 397 7484
Fax. +1 514 397 7600